Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More

Executive Summary

Califf was candid during an FDA Science Board meeting about the agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.

You may also be interested in...



Democrat, Republican Pioneer Women In US House Won’t Return After 2024 Elections

Granger’s exit means House Appropriations will have different chair no matter which party wins majority 2024 elections; Democrats will lose senior House Energy and Commerce Health Subcommittee member with Eshoo’s retirement.

After At-Home Diagnostics Got Boost From COVID, FTC Shows False Claims Didn’t End With Pandemic

FTC and California Attorney General offer CRI Genetics LLC as exhibit A for making good on promised deliverables for DNA-based ancestry and information reports.

Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation

Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel